{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"DLT was defined as any of the following: Treatment Emergent Adverse Events (AEs) occurring in Cycle 0 and Cycle 1 (total 4 weeks): Grade (G) 4 neutropenia lasting greater than (\\>)7 days; febrile neutropenia (absolute neutrophil count \\[ANC\\] less than (\\<)1,000 per millimeter cube (/mm\\^3) with single temperature \\>38.3 degree Celsius (deg C), or sustained temperature of greater than or equal to (\\>=) 38deg C for \\>1 hour \\[h\\]); G\\>=3 neutropenia with infection; G4 thrombocytopenia (unless the baseline count was \\>=25,000/mm\\^3 and \\<50,000/mm\\^3, in which case G4 thrombocytopenia was to be accompanied by \\>=G2 bleeding), Platelet count \\<10,000/mm\\^3 was considered a DLT irrespective of other factors; G3 thrombocytopenia with \\>=G2 bleeding; G4 AEs; G3 AE \\>=5 days despite optimal supportive care (except AEs attributed to cytokine release syndrome \\[CRS\\]); G3 CRS (except CRS that have not been maximally treated or improved to \\<=G1 within 48h); confirmed drug induced liver injury.","groups":[{"description":"Participants received an initial priming dose of 600 microgram per kilogram elranatamab subcutaneously on Cycle 0 Day 1 (7 days prior to Cycle 1 Day 1). During treatment cycle, participants were administered 1000 microgram per kilogram elranatamab weekly during each cycle (each cycle was of 3 weeks).","id":"OG000","title":"Elranatamab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Per Protocol Analysis Set included all enrolled participants who had at least 1 dose of study intervention and either experienced DLT or did not have major treatment deviations during the DLT observation period.","reportingStatus":"POSTED","timeFrame":"Up to 4 weeks","title":"Number of Participants With Dose Limiting Toxicities (DLTs)","type":"PRIMARY","unitOfMeasure":"Participants"}